Nytt patent för Infant Bacterial Therapeutics godkänt i Europa
June 15, 2023 09:45 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att Europeiska patentverket godkänt bolagets patentansökning för Lactobacillus reuteri. Patentet gäller läkemedelskandidaten IBP-9414, som för...
New patent for Infant Bacterial Therapeutics has been approved in Europe
June 15, 2023 09:45 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) announces today that the European Patent Office has approved its patent application for Lactobacillus reuteri. The patent pertains to the drug candidate...
2 Day Training Course on the FDA (Food and Drug Administration) Drug Approval Process: June 14-15, 2023
June 15, 2023 04:13 ET
|
Research and Markets
Dublin, June 15, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
IBT offentliggör prospekt
June 13, 2023 05:15 ET
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
IBT publishes prospectus
June 13, 2023 05:15 ET
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...
Extra bolagsstämma i Infant Bacterial Therapeutics
June 09, 2023 05:04 ET
|
Infant Bacterial Therapeutics AB
På extra bolagsstämman i Infant Bacterial Therapeutics AB (publ) den 9 juni 2023 beslutades att godkänna styrelsens beslut från den 16 maj 2023 om att bolagets aktiekapital ska ökas genom emission av...
Extraordinary General Meeting of Infant Bacterial Therapeutics
June 09, 2023 05:04 ET
|
Infant Bacterial Therapeutics AB
At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve the Board of Directors’ resolution from May 16, 2023 to increase the...
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
May 26, 2023 16:05 ET
|
Biodexa Pharmaceuticals PLC
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
May 24, 2023 08:40 ET
|
Biodexa Pharmaceuticals PLC
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
Global Orphan Diseases Partnering 2010-2023: the Full Collection of Orphan Diseases Disease Deals Signed Between the World's Pharmaceutical and Biotechnology Companies Since 2010
May 24, 2023 07:03 ET
|
Research and Markets
Dublin, May 24, 2023 (GLOBE NEWSWIRE) -- The "Global Orphan Diseases Partnering 2010-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.Global...